Financials
Financial year 2025
Research and Medical Distribution from Brugge, company number BE0744777876, closed financial year 2025 with a result of € -8,761 after tax. For that financial year Research and Medical Distribution recorded a gross margin of € 2,098 and equity of € 64,429. Compared with financial year 2024, the result moved from € 14,543 to € -8,761. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on May 18, 2026.
€ 64,429
▼ 12% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -8,761
▼ still € 14,543 profit in 2024
Profit after tax over the fiscal year.
€ 13,115
▼ 77% vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € 32,429.
People and assets in 2025
≈ 1
No payroll staff. One director, so that person most likely runs the business.
€ 21,599
▲ € 20,857 vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 20,461
▲ € 18,109 vs 2024
€ 12,420 is repaid this year. At this pace the long-term loan is gone in ≈ 2 years.
€ 19,856
▼ 65% vs 2024
Supplier invoices still open on the last day of the fiscal year.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 46,180 | € 36,169 | € 28,578 | € 2,098 | ▼ 93% |
| Profit after taxes | € 23,029 | € 19,176 | € 14,543 | € -8,761 | ▼ € 23,304 |
| Equity | € 79,471 | € 98,647 | € 73,190 | € 64,429 | ▼ 12% |
| Total debts | € 106,988 | € 60,463 | € 58,890 | € 40,317 | ▼ 32% |
| Cash | € 78,046 | € 77,358 | € 56,384 | € 13,115 | ▼ 77% |
| Retained profit | € 47,471 | € 66,647 | € 41,190 | € 32,429 | ▼ 21% |
| Dividend | € 0 | € 0 | € 40,000 | € 0 | ▼ 100% |
| Bank debt | € 5,593 | € 3,984 | € 2,352 | € 20,461 | ▲ € 18,109 |
| Balance sheet total | € 186,459 | € 159,110 | € 132,080 | € 104,746 | ▼ 21% |
Key figures of Research and Medical Distribution, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to Research and Medical Distribution?
What happened at Research and Medical Distribution in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: loss of € 8,761 (▼ € 23,304 vs 2024). Source: NBB ↗
- New establishment in Aalst. KBO
- Financial Management Bosmans BV became a director. NBB
- Nobilis Consulting BVBA became a director. NBB
- New establishment in Brugge. KBO
- Start of the company according to the CBE. KBO
In short
From € 23,029 profit in 2022 to € 8,761 loss in 2025.
Paid € 14,003 in corporate taxes since 2022.
Best year ever: 2022, with € 23,029 profit.
Paid out € 40,000 in dividends to the owners in total.
A new publication or filing at Research and Medical Distribution? We notify you, reason included.
Follow Research and Medical DistributionDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind Research and Medical Distribution are Peter Everaerts, Financial Management Bosmans BV and Nobilis Consulting BVBA. Financial Management Bosmans BV is also behind MERGAN&PARTNERS.
Directors
According to the 2025 annual accounts
Peter Everaerts
Director
Financial Management Bosmans BV
Managing director · represented by Jellen Bosmans
Also active at: MERGAN&PARTNERS
since 2022
Director · represented by Jelle Willems
since 2022
Establishments
Establishment units
Physical locations of this company
Rederskaai 39 box 501
8380 Brugge
Fonteinbos 23
9320 Aalst
Active since 1 June 2022
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 4 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0744.777.876
- VAT number
- BE 0744.777.876
- Registered office
- Rederskaai 39 bus 501, 8380 Brugge
- Names & denominations
- Research and Medical Distribution · ReMeDi
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 5 March 2020
- Peppol
- Active · Active since 27 Mar 2026
- Activities · NACE
Goederenvervoer over de weg